Otolaryngology Doctors in Durango, CO Accepting Medicare

4 Otolaryngology doctors found. Showing 1 - 4

Dr. William Thomas Williams, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 555 Rivergate Ste B1-105, C/o Curtis Powers-ackley, Durango, CO 81301 Phone: 970-749-1157

Dr. Philip David Wiley, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1165 S Camino Del Rio, Ste 200, Durango, CO 81303 Phone: 970-247-2920    Fax: 970-247-2923

Rachel B Cain, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1 Mercado St, Suite 205, Durango, CO 81301 Phone: 970-385-7272    Fax: 970-385-7299

Dr. Gregory Michael Schackel, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1 Mercado St, Suite 205, Durango, CO 81301 Phone: 970-385-7272    Fax: 970-385-7299

News Archive

New book from Fraser Institute discusses the government-run health insurance in Canada

As Americans debate the merits of a "public option" for health insurance, a new book published by the Fraser Institute, one of Canada's leading economic think tanks, documents the many significant problems with government-run health care in Canada, providing valuable comparative information for U.S. policy-makers at a crucial moment.

New guideline for juvenile idiopathic arthritis gives emphasis to disease-modifying treatments

The American College of Rheumatology will preview the 2021 Guideline for the Treatment of Juvenile Idiopathic Arthritis at ACR Convergence, the ACR's annual meeting.

Helix receives approval to conduct a clinical trial of Topical Interferon Alpha-2b in Sweden

Helix BioPharma today announced that it has received approval from Sweden's drug regulatory authority, the Medical Products Agency (MPA), to conduct a Phase II clinical trial of Topical Interferon Alpha-2b in patients with ano-genital warts (condylomata acuminata), who are positive for infection with the human papilloma virus (HPV).

Bayer's SAFYRAL oral contraceptive receives FDA approval

Bayer HealthCare Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new oral contraceptive (OC), SAFYRAL™ (drospirenone 3 mg/ ethinyl estradiol 30 mcg/ levomefolate calcium 451 mcg tablets and levomefolate calcium 451 mcg tablets). In women who choose an OC for birth control, SAFYRAL raises folate levels for the purpose of reducing the risk of rare neural tube defects (NTDs) in a pregnancy conceived while taking SAFYRAL or shortly after discontinuing it.

Report says FDA not up to scratch

According to a new report by the Institute of Medicine (IOM), despite the debacle following the drug Vioxx which was withdrawn from the market two years ago, few lessons have been learned and the Food and Drug Administration (FDA) in the U.S. still lacks the power and resources to adequately monitor the safety of newly-approved drugs.

Read more Medical News

› Verified 8 days ago